https://storage.courtlistener.com/recap/gov.uscourts.ndd.67917/gov.uscourts.ndd.67917.83.0.pdf
TLDR 340B in ND COURT
Federal Judge Daniel Traynor blocked North Dakota’s 340B contract-pharmacy law, but the striking part is not just the holding — it is his openly skeptical view of today’s 340B ecosystem. He sees the modern contract-pharmacy version of 340B as a program originally meant to help poor and underserved patients, but now increasingly used as a revenue-transfer engine for hospitals, contract pharmacies, and third-party administrators. Legally, he held that North Dakota’s law was not really a pharmacy-regulation law. In his view, it was a state attempt to rewrite the federal 340B bargain between manufacturers, HHS, and covered entities. He therefore found it preempted by federal law and, independently, invalid under the dormant Commerce Clause.
What the case was about
North Dakota passed H.B. 1473, a state law aimed at stopping drug manufacturers from limiting 340B access through contract pharmacies. Manufacturers have been trying to limit contract-pharmacy arrangements, often by requiring claims data or limiting delivery to one pharmacy, especially where a covered entity already has an in-house pharmacy. The Third Circuit and D.C. Circuit had already said the federal 340B statute does not require manufacturers to ship discounted drugs to unlimited numbers of contract pharmacies; the statute requires manufacturers to “offer” discounted drugs, but is silent on unlimited contract-pharmacy delivery. Judge Traynor quotes that line of cases and treats manufacturer conditions as allowed under federal law.
North Dakota tried to frame its law as a state pharmacy regulation — basically, “we are regulating pharmacies and drug delivery inside our state.” The judge did not buy that. He said Arkansas had previously defended a similar law as truly limited to delivery, and the Eighth Circuit treated Arkansas’s law that way. But North Dakota’s law, in his reading, was different: North Dakota did not define the law as only a delivery law and argued that it directly altered manufacturer conditions. That distinction is central.
The judge’s basic view of 340B
Judge Traynor’s introduction is unusually forceful. He begins with the sympathetic version of 340B: state laws like North Dakota’s “purport to protect the underdogs,” meaning facilities serving at-risk populations. But he immediately pivots: in his view, the program “meant to help American poor” is being abused to create a windfall to hospital conglomerates and participating pharmacies, and North Dakota’s law would “facilitate and sanction” that graft by intruding into federal law.
His economic description of 340B is straightforward. Congress created the 340B program in 1992 so eligible safety-net providers could obtain outpatient drugs at steeply discounted prices. The judge notes that discounts can be extreme — in some cases, “a penny per unit,” and he cites Farxiga as costing “hundreds of dollars” commercially but “less than a dollar” under 340B. The covered entity can then receive reimbursement at the ordinary insurance or Medicare/Medicaid price and keep the spread. Critically, he emphasizes that there is no statutory requirement that the 340B revenue be used directly to reduce drug costs for the patient.
That is the policy heart of the opinion: the judge sees a disconnect between 340B’s moral justification and 340B’s operational reality. The moral justification is helping needy patients. The operational reality, in his telling, is an arbitrage system where the patient often pays the same, the insurer pays the same, and the hospital/pharmacy/TPA ecosystem captures the margin.
His view of contract pharmacies and the replenishment model
Judge Traynor gives special attention to the replenishment model, which is probably the most important operational concept in the opinion. In the common model, pharmacies fill prescriptions at full price, with no patient discount at the point of sale. Later, third-party administrators review filled prescriptions and patient records to identify which prescriptions can be treated as 340B-eligible. Once enough eligible prescriptions are identified, the pharmacy orders discounted 340B replacement stock, which goes into general inventory. The wholesaler credits the pharmacy for the commercial price, charges the covered entity the 340B price, and seeks a manufacturer chargeback for the difference.
For a CMS-policy reader, the judge’s point is that this does not look like a simple safety-net discount flowing cleanly to vulnerable patients. It looks like a back-end claims-mining and margin-capture system. He stresses that pharmacies and TPAs take a percentage or fee per script, and that the filled prescription itself may have been paid at the normal price. This is why his opinion uses words like “windfall,” “graft,” “collusion,” and “fleeced.” Those are not neutral technocratic terms; they are a judicial description of a business model he views as gaming a federal program.
The “Big Pharma as victim” point
One of the most politically interesting passages is the judge’s acknowledgment that drug manufacturers are not sympathetic plaintiffs. He essentially says: yes, Big Pharma has money, drug prices are rising, and manufacturers love litigation. But those facts do not mean manufacturers can be “fleeced” by states, hospital conglomerates, and pharmacy interests.
This is important because it reframes the case. The judge is not writing a love letter to pharmaceutical companies. He is saying that unpopularity is not a legal theory. Even if manufacturers are politically unattractive plaintiffs, a state still cannot rewrite a federal program to transfer more money from manufacturers to in-state hospitals and pharmacies.
The key legal holding: federal preemption
The main legal holding is field preemption under the Supremacy Clause, tied to Congress’s Spending Clause power. Judge Traynor treats 340B as a federally designed bargain: if manufacturers participate in Medicare and Medicaid, they must offer covered outpatient drugs to covered entities at specified discounted prices. But the terms of that federal bargain are set by Congress and the federal program, not by individual states.
He writes that the 340B program does not invite state supplementation through cooperative federalism. In other words, this is not Medicaid managed care, where federal and state governments jointly administer a program. It is a federal drug-pricing program with federal terms. North Dakota’s law, he says, changes those terms by forcing manufacturers to accept contract-pharmacy arrangements and data limits that federal law does not require.
The judge’s cleanest legal sentence is that “the offer a 340B manufacturer makes to a 340B covered entity is governed by the 340B program and Congress. States have no part in that relationship.” That is the core preemption theory.
Why North Dakota lost the “we regulate pharmacies” argument
North Dakota tried to fit the case into traditional state police powers: states regulate pharmacies, delivery, health, and safety. Usually, courts are reluctant to find federal preemption in traditional health-and-safety areas. But Judge Traynor found that presumption did not apply because, in his view, North Dakota was not really regulating pharmacy practice. It was regulating manufacturer participation in a federal program.
He also makes a practical point: covered entities can still send drugs to whatever facility they choose. What changes is whether manufacturers must honor particular 340B pricing and delivery arrangements despite manufacturer conditions. Therefore, he concludes, the real target is not the pharmacy contract; it is the manufacturer’s federal-program offer.
Dormant Commerce Clause: the backup holding
Even if the law were not preempted, the judge says it would still fail under the dormant Commerce Clause. His reasoning is that North Dakota’s law effectively regulates transactions between out-of-state manufacturers and out-of-state wholesalers. The chargeback mechanism may be triggered by North Dakota-covered-entity activity, but the economic transaction being controlled is interstate and often outside North Dakota.
That matters because states generally cannot project their economic regulation into other states. North Dakota argued that many state laws have ripple effects beyond state borders. The judge agreed in principle but said this was not merely a ripple. In his view, the law directly controlled the price and amount of out-of-state sales by forcing manufacturer chargebacks that would not otherwise occur.
The bottom line for your CMS-policy brain
This opinion is not just “state law loses, pharma wins.” It is a broader judicial attack on the post-2010 340B contract-pharmacy economy. Judge Traynor sees a federal safety-net drug discount program that has drifted into a large-scale arbitrage system, with hospitals, pharmacies, and TPAs capturing value while patients often see no lower price. He is especially hostile to state laws that try to lock in or expand that arbitrage by overriding manufacturer restrictions.
For policy strategy, the opinion is valuable because it provides a judge-written narrative that 340B has become less like a patient-protection program and more like a federal price concession captured by institutions. For legal strategy, the key move is distinguishing “pharmacy regulation” from “regulation of federal-program manufacturer obligations.” That distinction lets him avoid the Arkansas precedent and reach a much more pharma-favorable result.
